Acelrx pharmaceuticals announces a second abstract on dsuvia® accepted for presentation at the anesthesiology® 2022 annual meeting

Experts from the uniformed services university of the health sciences conclude that future battlefield medicine efforts should focus on newer analgesics like dsuvia® across military settings and establish protocols for their implementation hayward, calif. , aug. 25, 2022 /prnewswire/ -- acelrx pharmaceuticals, inc. (nasdaq: acrx), (acelrx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that an abstract entitled, "evolution of opioid analgesia on the battlefield for moderate-to-severe acute pain" (abstract # a4123) was accepted for e-abstract presentation at the anesthesiology® 2022 annual meeting, being held october 21-25, 2022 in new orleans, la.
ACRX Ratings Summary
ACRX Quant Ranking